RE: New 52-week low?24 Feb 2026 17:43
All I've seen from QBT, for the years I've been watching the company, is narrative without substance. No tangible proof of progress and no revenue, just occasional pumping PRN's sometimes followed by placing's. Does anyone really believe this company will reward long term shareholders? Some people are making money out this stock, unfortunately they don't appear to be the long suffering shareholders. As much as I accept that someone should earn a wage for doing a job, I'm not sure this company can justify the wages it pays to Professor Gardin; While long term shareholders are crying into their soup, he appears to be laughing all the way to the bank. I wish I could find a high paying job that appears to have no responsibility related to performance and paying out a healthy annual wage. If QBT fails, Gardin might lose out on his shares, but he'll walk away with a very healthy bank account going off the amount of cash QBT are reported to be paying him through various vehicles.
From AI:
"how much is professor gardin earning from quantum blockchain technologies through various payment vehicles
Professor Francesco Gardin, CEO and Executive Chairman of Quantum Blockchain Technologies (QBT), receives compensation through multiple vehicles, primarily via consultancy fees paid to his company, Infusion, rather than as a direct salary. As of the most recent financial reports in 2025, his annualised consultancy earnings total £195,000, supplemented by one-off performance fees and commission rights.
London Stock Exchange
Breakdown of Compensation Vehicles
Consultancy Fees (via Infusion): Effective 1 January 2024, Gardin's monthly consultancy fee was increased from £12,500 to £16,250. This equates to a base annual earning of £195,000.
Performance Bonuses: For his contributions during 2024, the board awarded an additional one-off fee of £100,000.
Commission Rights: Gardin holds rights to a 10% commission on funds recovered from the company's legacy assets (specifically SIPIEM, Sosushi, Mediapolis, and Geosim).
Equity & Share Options: As of July 2025, Gardin beneficially owns 29,284,149 ordinary shares (approximately 2.00% of the company). He also manages a Sale & Repurchase Agreement (REPO) for an additional 5,000,000 shares, which was extended to 31 December 2025.
London Stock Exchange
Historical Earnings Context
The total amounts paid to Infusion for Gardin's services have fluctuated based on discretionary board awards:
2023: €288,000 total.
2022: €200,000 total"